| Date | Quarter | Session | EPS (est → actual) | Revenue (est → actual) |
|---|---|---|---|---|
| Oct 26, 2026Next | Q3 2026 | — | 4.80 | 3.87 B |
Aug 31, 2026
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory solutions, today announced enhancements to the digital experience of Labcorp Global Trial Connect™, the company's portfolio of clinical trial services, data and technology that enhances and accelerates delivery. The newly redesigned platform introduces new capabilities across the Labcorp Sponsor™ and Labcorp Investigator™ portal experiences of Global Trial Connect, providing greater visibility across studies, simplify
Aug 28, 2026
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, Sept. 15, at 11:30 a.m. ET.
Labcorp Holdings (NYSE: LH) introduced the Elecsys pTau-217 blood test, the first FDA-cleared single biomarker test for Alzheimer’s disease, expanding access through primary and specialty care. The Elecsys pTau-217 test is positioned to support clinical assessment of cognitive decline with a minimally invasive blood draw instead of more invasive procedures. Labcorp announced a long-term alliance with the National Association of Community Health Centers to support clinical leadership and...
Aug 26, 2026
Do Wall Street analysts favor Labcorp’s stock, given its solid performance?
Aug 25, 2026
Over the past six months, Labcorp has been a great trade, beating the S&P 500 by 9.5%. Its stock price has climbed to $339.34, representing a healthy 20% increase. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
LH's specialty-testing expansion, strategic partnerships and buybacks support growth, while reimbursement and cost pressures pose risks.
Aug 24, 2026
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys® pTau-217 test following clearance by the U.S. Food and Drug Administration (FDA). Developed by Roche Diagnostics, the blood test aids in identifying amyloid pathology associated with Alzheimer's disease in individuals 55 and older with signs, symptoms or complaints of cognitive decline. Elecsys® pTau-217 is the first and only FDA-cleared single-biomarker blood test
Elecsys® pTau-217 is the first and only FDA-cleared single-biomarker blood test to both rule in and rule out amyloid pathology across specialty and primary care settingsMeasures phosphorylated Tau 217 (pTau-217), an
Aug 18, 2026
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and the National Association of Community Health Centers (NACHC) today announced a strategic alliance to strengthen leadership development, support practice improvement and advance community health initiatives across the nation's Community Health Center (CHC) network. As part of the collaboration, the organizations are launching the NACHC Leadership Exchange for Chief Medical Officers, designed to support cu
Collaboration will support leadership development, practice improvement and innovation across the nation's Community Health CentersBURLINGTON, N.C. and BETHESDA, Md., Aug. 18, 2026 /PRNewswire/ -- Labcorp (NYSE:LH),
Aug 17, 2026
Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced it will host an Investor Day on Thursday, September 10, 2026, from 9 a.m. to noon ET.
Aug 12, 2026
Schechter maintains a $33 million stake after this pre-scheduled sale under a Rule 10b5-1 plan.
Labcorp Holdings (LH) is in focus after a series of oncology diagnostics approvals and launches, including the PGDx elio tissue complete CDx for advanced melanoma and nationwide access to Roche's VENTANA PTEN RxDx Assay for prostate cancer. See our latest analysis for Labcorp Holdings. Labcorp Holdings has attracted more attention in recent months, with oncology diagnostics approvals and stronger earnings updates sitting alongside a 30 day share price return of 16.48% and a 1 year total...
In late July and early August 2026, Labcorp reported higher second-quarter and year-to-date earnings, raised its 2026 revenue growth guidance, completed a large share repurchase program, and expanded its precision oncology offering by making Roche's FDA-approved VENTANA PTEN (SP218) RxDx Assay available nationwide to help guide prostate cancer treatment decisions. Together with the recent FDA approval of its PGDx elio tissue complete CDx for advanced melanoma, these developments reinforce...
Aug 10, 2026
LH enters late 2026 with stronger growth, margin gains and raised guidance, but a rich valuation and cost risks support a measured view.
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that the U.S. Food and Drug Administration (FDA) has approved Labcorp's PGDx elio® tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma with certain BRAF variants who may benefit from treatment with FDA-approved targeted therapiesi.
Aug 7, 2026
LH shares surged 14% in a month as stronger earnings, margin gains and growth collide with a valuation above the company's five-year median.
